The collaboration will analyse the response of a targeted therapy in different cancer types and stratify patients to provide a more individualized cancer treatment with Apceth’s cell and gene therapeutics.
A biomarker platform will enable oncologists to identify those patients who will most likely benefit from the treatment with Apceth’s therapeutics.
Apceth will leverage Indivumed’s highly regarded tumor tissue bank and its expertise in tissue-based biomarker discovery and validation.